NCT07044336 (ClinicalTrials.gov Identifier: NCT07044336) is a Phase 3 clinical trial evaluating puxitatug samrotecan (also known as AZD8205 or Puxi-Sam), an investigational antibody-drug conjugate targeting B7-H4, compared to physician’s choice of standard chemotherapy (doxorubicin or paclitaxel) in adult female patients with B7-H4-selected advanced or metastatic endometrial cancer (including endometrial carcinoma or carcinosarcoma) that has progressed on or after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. The trial is a multicenter, global, randomized, open-label study sponsored by AstraZeneca.

“OSF HealthCare is deeply committed to advancing care for patients with gynecologic malignancies, including the significant challenges of advanced or metastatic endometrial cancer,” said Dr. Michelle Rowland, Translational Researcher and Gynecologic Oncologist, OSF HealthCare Cancer Institute. “Clinical trials like this one offer eligible patients the opportunity to receive promising investigational therapies under exceptionally close medical supervision, while directly contributing to the generation of high-quality data that can improve treatment approaches for future patients and help accelerate meaningful progress in the field.”

The study is designed to assess whether the investigational therapy improves progression-free survival and overall survival compared to chemotherapy, while also evaluating response rates, duration of response, quality of life impacts, and safety profiles. All treatment approaches are studied for research purposes in accordance with the approved study protocol, with rigorous monitoring to generate high-quality data on efficacy and tolerability in this pretreated patient population.

Donors and researchers interested in supporting or collaborating on oncology initiatives at OSF HealthCare are invited to connect with our team by calling (844) 673-4467 or emailing sfmc.clinicaltrials@osfhealthcare.org.